Literature DB >> 18458534

Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: Implications for the response to hormonal therapy.

Isabelle Mercier1, Mathew C Casimiro, Chenguang Wang, Anne L Rosenberg, Judy Quong, Alimatou Minkeu, Kathleen G Allen, Christiane Danilo, Federica Sotgia, Gloria Bonuccelli, Jean-François Jasmin, Huan Xu, Emily Bosco, Bruce Aronow, Agnieszka Witkiewicz, Richard G Pestell, Erik S Knudsen, Michael P Lisanti.   

Abstract

It is becoming increasingly apparent that the tumor microenvironment plays a critical role in human breast cancer onset and progression. Therefore, we isolated cancer-associated fibroblasts (CAFs) from human breast cancer lesions and studied their properties, as compared with normal mammary fibroblasts (NFs) isolated from the same patient. Here, we demonstrate that 8 out of 11 CAFs show dramatic downregulation of caveolin-1 (Cav-1) protein expression; Cav-1 is a well-established marker that is normally decreased during the oncogenic transformation of fibroblasts. Next, we performed gene expression profiling studies (DNA microarray) and established a CAF gene expression signature. Interestingly, the expression signature associated with CAFs encompasses a large number of genes that are regulated via the RB-pathway. The CAF gene signature is also predictive of poor clinical outcome in breast cancer patients that were treated with tamoxifen mono-therapy, indicating that CAFs may be useful for predicting the response to hormonal therapy. Finally, we show that replacement of Cav-1 expression in CAFs (using a cell-permeable peptide approach) is sufficient to revert their hyper-proliferative phenotype and prevent RB hyper-phosphorylation. Taken together, these studies highlight the critical role of Cav-1 downregulation in maintaining the abnormal phenotype of human breast cancer-associated fibroblasts.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18458534      PMCID: PMC6688494          DOI: 10.4161/cbt.7.8.6220

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  75 in total

1.  Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment.

Authors:  Ubaldo E Martinez-Outschoorn; Casey Trimmer; Zhao Lin; Diana Whitaker-Menezes; Barbara Chiavarina; Jie Zhou; Chengwang Wang; Stephanos Pavlides; Maria P Martinez-Cantarin; Franco Capozza; Agnieszka K Witkiewicz; Neal Flomenberg; Anthony Howell; Richard G Pestell; Jaime Caro; Michael P Lisanti; Federica Sotgia
Journal:  Cell Cycle       Date:  2010-09-09       Impact factor: 4.534

Review 2.  The autophagic tumor stroma model of cancer or "battery-operated tumor growth": A simple solution to the autophagy paradox.

Authors:  Ubaldo E Martinez-Outschoorn; Diana Whitaker-Menezes; Stephanos Pavlides; Barbara Chiavarina; Gloria Bonuccelli; Trimmer Casey; Aristotelis Tsirigos; Gemma Migneco; Agnieszka Witkiewicz; Renee Balliet; Isabelle Mercier; Chengwang Wang; Neal Flomenberg; Anthony Howell; Zhao Lin; Jaime Caro; Richard G Pestell; Federica Sotgia; Michael P Lisanti
Journal:  Cell Cycle       Date:  2010-11-30       Impact factor: 4.534

3.  Low α(2)β(1) integrin function enhances the proliferation of fibroblasts from patients with idiopathic pulmonary fibrosis by activation of the β-catenin pathway.

Authors:  Hong Xia; Jeremy Seeman; Jian Hong; Polla Hergert; Vidya Bodem; Jose Jessurun; Karen Smith; Richard Nho; Judy Kahm; Philippe Gaillard; Craig Henke
Journal:  Am J Pathol       Date:  2012-05-27       Impact factor: 4.307

4.  Inactivation of Rb in stromal fibroblasts promotes epithelial cell invasion.

Authors:  Adam Pickard; Ann-Christin Cichon; Anna Barry; Declan Kieran; Daksha Patel; Peter Hamilton; Manuel Salto-Tellez; Jacqueline James; Dennis J McCance
Journal:  EMBO J       Date:  2012-05-29       Impact factor: 11.598

Review 5.  Targeting the tumour stroma to improve cancer therapy.

Authors:  Kenneth C Valkenburg; Amber E de Groot; Kenneth J Pienta
Journal:  Nat Rev Clin Oncol       Date:  2018-06       Impact factor: 66.675

6.  An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial Akt activation.

Authors:  Dolores Di Vizio; Matteo Morello; Federica Sotgia; Richard G Pestell; Michael R Freeman; Michael P Lisanti
Journal:  Cell Cycle       Date:  2009-08-27       Impact factor: 4.534

Review 7.  Warburg meets autophagy: cancer-associated fibroblasts accelerate tumor growth and metastasis via oxidative stress, mitophagy, and aerobic glycolysis.

Authors:  Stephanos Pavlides; Iset Vera; Ricardo Gandara; Sharon Sneddon; Richard G Pestell; Isabelle Mercier; Ubaldo E Martinez-Outschoorn; Diana Whitaker-Menezes; Anthony Howell; Federica Sotgia; Michael P Lisanti
Journal:  Antioxid Redox Signal       Date:  2011-11-17       Impact factor: 8.401

8.  Absence of caveolin-1 expression in carcinoma-associated fibroblasts of invasive micropapillary carcinoma of the breast predicts poor patient outcome.

Authors:  Meijing Ren; Fangfang Liu; Yufen Zhu; Yaqing Li; Ronggang Lang; Yu Fan; Feng Gu; Xinmin Zhang; Li Fu
Journal:  Virchows Arch       Date:  2014-07-01       Impact factor: 4.064

Review 9.  Anti-inflammatory/antioxidant use in long-term maintenance cancer therapy: a new therapeutic approach to disease progression and recurrence.

Authors:  Sarah Crawford
Journal:  Ther Adv Med Oncol       Date:  2014-03       Impact factor: 8.168

10.  Caveolin-1-/- null mammary stromal fibroblasts share characteristics with human breast cancer-associated fibroblasts.

Authors:  Federica Sotgia; Francesco Del Galdo; Mathew C Casimiro; Gloria Bonuccelli; Isabelle Mercier; Diana Whitaker-Menezes; Kristin M Daumer; Jie Zhou; Chenguang Wang; Sanjay Katiyar; Huan Xu; Emily Bosco; Andrew A Quong; Bruce Aronow; Agnieszka K Witkiewicz; Carlo Minetti; Philippe G Frank; Sergio A Jimenez; Erik S Knudsen; Richard G Pestell; Michael P Lisanti
Journal:  Am J Pathol       Date:  2009-03       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.